PEAR Therapeutics

PEAR Therapeutics is a biotechnology and software company offering prescription digital therapeutics (PDTs) that is headquartered in Boston, Massachusetts and was founded in 2013 by Corey McCann, Stephen Smith, and William Greene. Prescription digital therapeutics made by PEAR Therapeutics are software-based treatments for disease in therapeutic areas such as psychiatric and neurological diseases. PEAR Therapeutics was the first company in the world to receive approval from the Food and Drug Administration (FDA) for PDTs claiming to improve the clinical outcomes of disease.

On January 2, 2018 PEAR Therapeutics completed their series B funding round with $50 million in funding from Temasek (lead investor), AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. The company plans on using the funding to continuing the development and commercialization of their PDT platform. Corey McCann, the CEO, president, and co-founder of PEAR Therapeutics made the following statement regarding on how the company plans on using their series B funding:

This latest financing recognizes the strides we’ve made in proving the clinical utility and commercial viability of prescription digital therapeutics.

On January 4, 2019 PEAR Therapeutics completed their series C funding round with $64 million in funding from Temasek (lead investor), Novartis, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, The Bridge Builders Collaborative, EDBI, Blue Water Life Science Fund, LP., and Trustbridge Partners. The CEO, president, and co-founder of PEAR Therapeutics made the following statement regarding how the company plans on using their series C funding:

Pear now kicks off 2019 with additional capital to bring PDTs to patients. We look forward to establishing PDTs as a widespread modality for directly treating a range of serious diseases.